research is fundamental.
Pancreatic cancer research is advancing faster than ever before, driving new breakthroughs in early detection, drug development and precision medicine, giving patients the best chance for survival and quality of life. The Lustgarten Foundation is fueling the research at the center of these transformational developments. With the LABS Program, strategic research partnerships, and a bold, creative approach to understanding and treating this devastating disease, we are uniquely positioned to innovate and focus on high-risk, high-reward science that will give patients and their families more time together.

318 research projects across 81 academic institutions

100% of all donations fund pancreatic cancer research
research is fundamental.

$250 million invested in research since inception
Guided by our mission to transform pancreatic cancer into a curable disease, Lustgarten is accelerating progress to provide a more hopeful future for all patients. Lustgarten’s collaborative, science-focused strategy drives outcomes across the Foundation’s three research pillars—early detection, new drug development, and personalized medicine—with a concentration on translating our understanding of the underlying biology of pancreatic cancer into clinical application for patients.

While 2022 continued to be uniquely challenging, we are grateful to the pancreatic cancer research community for implementing bold approaches to save lives. And you, the Lustgarten community, are as essential to advancing research as every investigator we fund. Critical breakthroughs would not be possible without Lustgarten’s dedicated community of donors, volunteers, fundraisers, and corporate partners. Your persistence and energy inspire us daily; your continued support of our mission allows us to wield the power of research to extend lives.

Led by Lustgarten and powered by you, we are building momentum for the decade ahead—and beyond—to help pancreatic cancer patients not just survive but thrive. We are developing innovative new grant programs, expanding collaborations, establishing a network of LABS sites, broadening our early detection research, and training the next generation of scientists to ensure the continuity and advancement of progress for patients.

While the future is here with startling progress in cancer vaccine development, funded by Lustgarten, the trends in pancreatic cancer are deeply worrisome. Although pancreatic cancer accounts for only 3% of new cancer diagnoses in the United States, it accounts for 8% of cancer deaths. Research predicts pancreatic cancer will become the second deadliest cancer in the United States by 2030, second only to lung cancer. From 2001 to 2018, incidence rates of pancreatic cancer increased by 1% per year among both men and women; from 2001 to 2019, death rates increased by 0.2% per year for both sexes. Any increase in incidence and decrease in survival rates is concerning and reflects both the difficulty of diagnosing pancreatic
cancer early and the complexities of treating it. Data like these reinforce the urgent need for research. Thanks to you, we are positioned to meet this challenge and drive progress.

Led by the vision of our founders and highly motivated Board of Directors, we—and our deep bench of investigators—will continue to forge ahead to change disease outcomes benefiting the pancreatic cancer community. Your unwavering support since our founding in 1998 has allowed us to invest more than $250 million in high-risk, high-reward science while being mindful that equity, diversity, and inclusion across the research we fund and the scientists we support strengthen outcomes. Community is power, and we are stronger because of you.

Thanks to you, the Lustgarten Foundation is the backbone and anchor of the pancreatic cancer community. You are our inspiration and the reason we will keep pushing forward. As we commemorate our 25th anniversary this year, we are rededicating ourselves to what matters most: pursuing life-saving research. Together we will make 2023 a landmark year of discoveries when people with pancreatic cancer have more treatment options, better outcomes, and more time with loved ones.

With Hope and Gratitude,

Andrew Lustgarten
Chairman of the Board of Directors, Lustgarten Foundation; Director, MSG Sports Corp.

Linda Tantawi
CEO, Lustgarten Foundation

Kerri Kaplan
President, Lustgarten Foundation
Lustgarten-funded science has been a driving force in every major development in pancreatic cancer research since our founding in 1998. As the world’s largest private funder of pancreatic cancer research, we aim to advance breakthroughs in the understanding of the initiation and progression of pancreatic cancer to improve the diagnosis and treatment of the disease, providing more hope for the future.

Our comprehensive program focuses on early detection, new treatment development, and personalized medicine so we can bring the most cutting-edge research from the lab bench to the clinic, where it can be tested on patients, with the goal of giving patients a better quality of life and the hope for a cure.
Lustgarten Foundation’s Guiding Research Principles:

Support innovative research to fill knowledge gaps

Take large risks to drive new research opportunities and promising initiatives

Create and sustain partnerships with stakeholders and other funders that leverage resources and complement strengths to fill gaps and remove barriers

Cultivate collaboration to bring required expertise to the field and address specific challenges
First Pancreatic Cancer Prevention Vaccine Trial Underway

Elizabeth Jaffee, MD, the Lustgarten Foundation’s Chief Medical Advisor and leader of one of the LABS sites at Johns Hopkins, directs the first-ever vaccine trial aimed at preventing pancreatic cancer in healthy individuals with an elevated risk for the disease based on their genetics or family history of pancreatic cancer. Dr. Jaffee’s Phase 1 study is currently enrolling 25 participants and will measure the safety and immune response to a vaccine against mutant KRAS proteins, the most common driver of pancreatic cancer. A mutation in the KRAS gene is one of the first events to transform normal cells into pre-cancer and then cancer. Pre-cancerous lesions in the pancreas take almost 11 years to become cancerous, offering a tremendous window of opportunity for intervention. If deemed safe and effective, the next step is to determine if immunity against this mutated protein is able to delay or prevent pancreatic cancer.
This trial builds on Dr. Jaffee’s safety study involving 12 patients with early-stage pancreatic cancer who had already undergone surgery. According to findings reported in the October 10, 2022, issue of *The New York Times* (“After Giving Up on Cancer Vaccines, Doctors Start to Find Hope,” by Gina Kolata), none of those patients have had a recurrence two years later. In this study, the vaccine worked by training white blood cells called T cells to recognize cells containing one of the six specific gene mutations driving pancreatic cancer growth in the majority of patients and kill them.

This cancer prevention vaccine research is funded by the Pancreatic Cancer Collective, an initiative of the Lustgarten Foundation and Stand Up To Cancer to improve pancreatic cancer patient outcomes.

New Results from the Cancer of the Pancreas Screening-5 Study (CAPS-5)

Screening for high-risk patients is critically important to our Lustgarten community. A recent report from the Cancer of the Pancreas Screening-5 Study (CAPS-5) published online in the *Journal of Clinical Oncology* found regular screenings with MRIs or endoscopic ultrasounds can lead to early-stage detection and long-term survival. Investigators at Johns Hopkins and seven other medical centers enrolled people who had a genetic variant, raising their risk for pancreatic cancer, or who had more than one first-degree relative (parent, sibling, child) with pancreatic cancer. According to the study, the five-year survival of patients with pancreatic cancer detected by screening is 73%, and the median overall survival is nearly 10 years, compared with 18 months for patients diagnosed with pancreatic cancer outside of surveillance.

The CAPS-5 Study is funded by a Stand Up To Cancer-Lustgarten Foundation Pancreatic Cancer Interception Translational Research Grant, and the Lustgarten Foundation has also funded previous CAPS studies since 1998.

“Collaborations help make more advances. If I look at what the pancreatic cancer expert field looked like even 20 years ago, there were so few of us, and now we have some of the smartest scientists, some of the smartest clinical researchers, very interested in working on pancreatic cancer. We are going to make a difference. I can’t say exactly what is going to happen, but it is going to happen.”

Elizabeth Jaffee, MD
Chief Medical Advisor and Leader of the TAG, Lustgarten Foundation
Early Detection and Interception

Research Projects with Dr. Alison Klein and Dr. Laura D. Wood

Alison Klein, PhD, Professor of Oncology, Johns Hopkins School of Medicine, is using updated ways of sequencing genes (including long-read sequencing, a DNA sequencing technique to identify long sequences of DNA, and machine learning) to determine if there are other genes besides the ones already known to increase the risk for pancreatic cancer in families. This is critical because in approximately 80% of families with inherited pancreatic cancer, the gene causing the risk is unknown. Prior Lustgarten-funded research conducted by the Pancreatic Cancer Genetic Epidemiology Consortium, co-led by Dr. Alison Klein and Dr. Gloria Petersen, resulted in the discovery of pancreatic cancer risk genes, including ATM and PALB2.

Laura D. Wood, MD, PhD, Associate Professor, Johns Hopkins University, developed CODA, a three-dimensional modeling technique using slices of tissues to build a model showing what happens when cells touch other cells to determine if that interaction has an impact on pancreatic cancer development. She is looking at the cellular and molecular alterations associated with increased risk in patients with older age and familial pancreatic cancer. Using CODA, she will analyze normal pancreatic tissue and examine the specific cellular and molecular changes that occur in older patients who are at an increased familial risk. Dr. Wood is also examining people with precancerous lesions called PanINs to understand what causes a lesion to change from benign, which requires monitoring, to malignant, which requires surgical intervention.

Dr. Klein and her team aim to:

- Identify genetic causes of familial pancreatic cancer
- Discover new candidate pancreatic cancer genes that were not found using short-read sequencing
- Identify families with genetic variants in known pancreatic cancer genes that were missed using conventional sequencing approaches
- Create new algorithms to identify the cause of inherited diseases including cancers
- Develop effective methods for large-scale, long-range genomic sequencing so doctors can monitor for risk in their patients
The Lustgarten Foundation’s unrelenting, 25-year commitment to funding basic science has led to an improved understanding of the biology underlying pancreatic cancer, resulting in the identification of new dependencies that can be pursued therapeutically.

As a force for progress in the scientific community, the Lustgarten Foundation’s research initiatives are focused on projects to identify novel drug targets and develop and advance preclinical and clinical testing of new drugs and drug combinations in pancreatic cancer.

A hallmark of the Lustgarten Foundation’s unique research strategy, the LABS Program provides long-term funding to promote the development of innovative ideas and speed the pace of discovery by incentivizing interdisciplinary team science.

Guided by our patient-centered mission and science-driven strategy, Lustgarten supports flexibility, fearlessness, creative confidence, and a culture of innovation and dedication to scientific rigor. The LABS Program is committed to sharing expertise across diverse fields with the goal of advancing knowledge and refining our collective understanding of complex systems and pathways.
"We are honored to be the first LABS site on the West Coast. For the first time, we’ve created a collaborative space on campus—the Lustgarten Center—for each of our four participating labs to share equipment and resources. This allows researchers to bring their individual areas of complementary expertise to bear on the shared goal of curing pancreatic cancer."

Reuben Shaw, PhD  
Director of the LABS site, Salk Institute

With the Lustgarten Foundation’s broad vision and dynamic strategy, each of the institutions participating in the LABS Program brings unique ideas and strengths to solve the most challenging problems of pancreatic cancer.

Cold Spring Harbor Laboratory  
Leader: David Tuveson, MD, PhD

Dana-Farber Cancer Institute  
Leader: Brian Wolpin, MD, MPH

Johns Hopkins (2 LABS sites)  
Leaders: Bert Vogelstein, MD and Elizabeth Jaffee, MD

Massachusetts Institute of Technology  
Leader: Tyler Jacks, PhD

Salk Institute  
Leader: Reuben Shaw, PhD

In 2022, the Lustgarten Foundation launched a new strategic partnership with the prestigious Salk Institute in La Jolla, CA—the first LABS site on the West Coast. The researchers participating in this five-year, $5 million collaboration are working to identify and validate new targets for pancreatic cancer drugs and biomarkers, with the goal of advancing the most promising discoveries to the next stage of drug and biomarker discovery and development. Led by Reuben Shaw, PhD, Director of Salk’s National Cancer Institute-designated Cancer Center, and co-principal investigators Ronald Evans, PhD, Tony Hunter, PhD and Dannielle Engle, PhD, the Salk Dedicated Program in Pancreatic Cancer expands on the Salk Institute’s core strength of attacking cancer from multiple angles.
The CAI reduces the time from clinical trial concept to launch by using a Lustgarten-developed process based on the best available science and employing innovative biomarkers. These “smarter” clinical trials generate large volumes of data scientists use to help inform and improve current and future clinical trials and expedite new treatments.

The Foundation has invested $6.1 million in four CAI studies:

Two studies, one for metastatic patients and one for patients in the neoadjuvant (pre-surgery) setting, examine new combinations of vaccines and drugs targeting the immune system to determine if they can prevent tumors from becoming resistant to immunotherapies.

The third study evaluates a new combination of drugs to simultaneously activate the T cells (a type of immune cell) and block the inhibitory signals from the tumor.

The fourth CAI-funded study is a Phase II trial assessing a new drug combination to prevent chemotherapy resistance in metastatic pancreatic cancer patients.

Translational Advisory Group (TAG)

The TAG drives success of the CAI by identifying, soliciting, vetting, and developing new clinical trial concepts, based on the best available science. CAI studies are typically small, enrolling 10–20 patients, enabling the researchers to deeply analyze each patient and extract the most information possible.

TAG members represent the following institutions:
- Dana-Farber Cancer Institute
- Duke University
- Johns Hopkins
- Massachusetts General Hospital
- Memorial Sloan Kettering Cancer Center
- Northwell Health
- NYU Langone
- Oregon Health & Science University
- Princess Margaret Cancer Centre
- UC San Diego
- University of Pennsylvania

$6.1M
Invested in 4 CAI Studies

3
Studies Focused on Immunotherapy

1
Study Focused on Chemotherapy Resistance
Pancreatic Cancer Collective (PCC)

To hasten the Foundation’s impact on pancreatic cancer research, the Lustgarten Foundation has collaborated with Stand Up To Cancer (SU2C) since 2012. The PCC supports groundbreaking progress in identifying new treatments for pancreatic cancer and improving patient outcomes.

Results of a Phase I Trial of Adjuvant, Individualized mRNA Neoantigen Vaccine

At the American Society of Clinical Oncology’s (ASCO) 2022 annual meeting, Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center, presented the results of the first trial testing a personalized messenger RNA (mRNA) vaccine. The two-year, Phase 1 trial was the culmination of years of research leading to the critical discovery that long-term pancreatic cancer survivors have specific immune responses the team hoped to mimic with the vaccines. The ASCO presentation followed the team's second paper published in the June 9, 2022, issue of the scientific journal *Nature*.

In this trial, half of the 16 patients treated showed an immune response to the vaccine. Of those eight patients, none showed recurrence for up to 30 months (median follow-up 18 months) and they continue to be followed. In contrast, patients who didn’t respond to the vaccine had a median recurrence-free survival of just over a year. The results suggest the possibility of durable protection against pancreatic cancer if an immune response can be driven against tumor-specific targets. The study also demonstrates the feasibility of developing patient-specific, personalized vaccines in a clinically relevant timeframe.

The trial is funded by the Pancreatic Cancer Collective, a partnership between the Lustgarten Foundation and Stand Up To Cancer to improve pancreatic cancer patient outcomes.
Break Through Cancer created a “team lab” structure to maximize interdisciplinary collaboration among researchers and is the first-of-its-kind model for collaboration. Researchers across these five institutions will investigate promising KRAS-targeting therapies to accelerate the translation of new KRAS inhibitors into effective drugs for this disease:

Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Koch Institute for Integrative Cancer Research at MIT
The University of Texas MD Anderson Cancer Center

Making a Direct and Lasting Impact on Pancreatic Cancer: Glenn W. Bailey Foundation Provides a Legacy of Hope

In 2022, the Glenn W. Bailey Foundation gave a $1.2 million gift to support the Robert F. Vizza Lustgarten Foundation’s Clinical Accelerator Initiative (CAI). This gift honors the legacy of Glenn W. Bailey, who passed away from pancreatic cancer in 2007. His late wife, Cornelia T. Bailey, first contributed to the Lustgarten Foundation after his death, allocating donations for general research and later through her Foundation for projects including the Dedicated LABS Program and the PASS-01 clinical trial.

The Glenn W. Bailey Foundation is committed to ensuring the United States remains a global thought leader in all forms of science, technology, engineering, math, and medical research. In support of the Glenn W. Bailey Foundation’s commitment to bringing research from the lab to the clinic even faster, this generous $1.2 million donation is earmarked for the CAI.

"As a foundation, we are committed to providing funding for these important clinical trials. We realized we had the capacity to increase our giving and felt confident this is the perfect time to invest in pancreatic cancer research, so we can help scientists who are already on the cusp of important discoveries make even more progress toward a cure," said Stephen Vogelsang, Glenn W. Bailey Foundation Board member. "And, with the Lustgarten Foundation’s commitment to donating 100% of every dollar to fund the most groundbreaking research, we feel confident patients will significantly benefit from this gift," added Eileen Daly, another Glenn W. Bailey Foundation Board member.
PASS-01 Trial: Predicting Tumor Response

Pancreatic cancer researchers from the United States and Canada are conducting the PASS-01 trial to predict which of the two standard-of-care treatment regimens will work best for individual pancreatic cancer patients based on the molecular traits of their tumors. This landmark study is the first head-to-head comparison of the two standard-of-care chemotherapy regimens for metastatic pancreatic cancer and will include an in-depth analysis of each participant’s tumor and response to therapy. Among the multitude of approaches being implemented in this study, researchers are using organoids to analyze pancreatic tumor biology and drug sensitivity for the first time in a clinical trial of this size.

The data generated from organoids in the PASS-01 study will help determine if this technology can be used to predict the most effective treatment for each patient. If successful, this trial can pave the way for organoids to personalize therapies for metastatic pancreatic cancer patients.

The organoid work for the PASS-01 trial is being conducted at the state-of-the-art organoid testing facility at Cold Spring Harbor Laboratory, where researchers are growing and testing organoids for trial participants. Additionally, this organoid research will help determine if neither of the standard-of-care options is likely to help a patient, so a patient’s doctor can pursue a different avenue of treatment.

Enrollment is progressing. In 2022, the Lustgarten Foundation opened a new trial site at the British Columbia Cancer Agency in Vancouver, Canada.

“Medical research advances evidence-based medicine. It supports the quality of life of individual patients, like me. It contributes to scientific advances which benefit the lives of others and future generations. We all stand on the shoulders of giants.”

-PASS-01 clinical trial participant at Princess Margaret Cancer Centre, Canada

The PASS-01 trial research taking place at Cold Spring Harbor Laboratory is funded in part through the Gail V. Coleman and Kenneth M. Bruntel Organoids for Personalized Therapy Grant.
Lustgarten’s Commitment to Equity, Diversity, and Accessibility

Solving the complex problem of pancreatic cancer requires a diversity of thought, education, training, background, and experience of the scientists investigating the disease, as well as diversity within patient data and those participating in clinical studies.

Career Development Awards Honoring Ruth Bader Ginsburg and John Robert Lewis

These awards were created to foster and grow the number of early-career women and underrepresented scientists receiving funding for pancreatic cancer research and to honor the lives and legacies of two iconic Americans lost to pancreatic cancer.

Administered by the American Association for Cancer Research (AACR), the awards support trailblazing investigators committed to increasing our understanding and treatment of the disease. Each recipient is awarded a three-year, $300,000 grant for their pancreatic cancer research.

2022 Recipients:

Career Development Award in Honor of Ruth Bader Ginsburg

Pingping Hou, PhD, an assistant professor at Rutgers University, is investigating an immune cell population called tumor-associated macrophages (TAMS) that has been shown to cause resistance in a therapy targeting KRAS, a key driver of pancreatic cancer.

School of Medicine and Dentistry

We gratefully acknowledge Jeannette & Stephen Kordiak for supporting the 2022 Lustgarten AACR Career Development Award for Pancreatic Cancer Research in honor of Ruth Bader Ginsburg.

Career Development Award in Honor of John Robert Lewis

Edwin Manuel, PhD, an assistant professor at the Beckman Research Institute of the City of Hope, is developing new methods to combat pancreatic cancer therapeutic resistance and adaptation, key components leading to disease progression.

"Lustgarten essentially started the field [of pancreas cancer research] by generating excitement about it and encouraging scientists to work on pancreas cancer. Now, we are using that influence to help close the gap in the rates of early-career women and underrepresented scientists applying for and receiving funding."

David Tuveson, MD, PhD
Chief Scientist, Lustgarten Foundation,
Director, LABS site at Cold Spring Harbor Laboratory
The Lustgarten Equity, Accessibility, and Diversity (LEAD) Project

The Lustgarten Equity, Accessibility, and Diversity (LEAD) Project was created to increase the recruitment and retention of underrepresented groups in pancreatic cancer clinical trials. The inaugural LEAD grant was awarded to Jen Jen Yeh, MD, Professor and Vice Chair of Research, Surgery, Division of Oncology Professor, Pharmacology Member, UNC Lineberger Comprehensive Cancer Center, for the PROmoting CliNical Trial Engagement for Pancreatic Cancer App Study (PROCLAIM Study). As a grant recipient, Dr. Yeh will receive $150,000 per year for three consecutive years to support her research.

Dr. Yeh’s PROCLAIM Study, in partnership with Dr. Ugwuji Maduekwe, MD, and her team at the Medical College of Wisconsin, will focus on breaking down barriers to recruiting diverse populations, such as distrust, poor communication, racial bias, and culturally discordant clinical trial materials, via a mobile health technology initiative. Mobile health technology will be used as an educational and communication tool fostering open discussion between Black people with pancreatic cancer and their cancer teams, increasing clinical trial participation.

“I am grateful to the Lustgarten Foundation for supporting this study and the important work we will do to break barriers in pancreatic cancer clinical trial participation of underrepresented groups.”

Jen Jen Yeh, MD
Professor and Vice Chair of Research, Surgery, Division of Oncology Professor, Pharmacology Member, UNC Lineberger Comprehensive Cancer Center

2021 and 2022 award grantees Drs. Manuel, Engle, Posey and Hou, and Andrew Rakeman, PhD, Lustgarten’s VP of Research, attend the AACR annual meeting.
Probing Racial Disparities in Pancreatic Cancer
Howard Crawford, PhD, Scientific Director, Henry Ford Pancreatic Cancer Center, is leading research analyzing existing tumor samples to determine if genomic and cellular differences may account for the higher rates and poorer outcomes of pancreatic cancer in Black Americans.

This study is funded in part through a grant from Bristol Myers Squibb.

LustgartenLIVE! is a live-streaming series of webinars created to foster awareness and education of our mission with best-in-class experts from leading cancer centers and businesses in research, technology, and science.

Our 2022 LustgartenLIVE! events covered the following topics:
The Power of Persistence: Women Transforming Cancer Research and Care
From the Clinic to the Lab, To You: How Research, Led by Lustgarten, is Transforming Patient Care at Your Local Cancer Center
Leading the Way: Equity, Accessibility, and Diversity in Pancreatic Cancer Research
The Intersection of Science and Technology: Advancing Patient Care
Progress and Promise 2022: The Foundation’s Year-End Report

Thank you to our Sponsors: Presenting: ViewRay Technologies; Series: Ipsen; Event: Bristol Myers Squibb, Miami Cancer Institute, Northwell Health Cancer Institute, Novocure, and Rolfe Pancreatic Cancer Foundation.

Exploring New Avenues for Treatment: Therapeutics-Focused Research Program
The Therapeutics-Focused Research Program is deepening the scientific and medical community’s understanding of the causes of pancreatic cancer and developing a robust pipeline of potential new treatment options.

This $11.2 million grant program promotes collaboration across labs and is expected to identify new therapeutic approaches and drug targets. Ten projects were selected for funding focusing on key areas of pancreatic cancer biology.
100% of donations fund pancreatic cancer research.
Community is Power

Together we ARE transforming pancreatic cancer into a curable disease.

24
Walks for Research

94
Other Events

653
Walk Teams

$2.8M
Raised by YOU in 2022
Northwell Health was the Presenting Sponsor of the 2022 New York metropolitan area walks. Thank you, Northwell Health, for your collaboration and your commitment to supporting pancreatic cancer patients.

10,329 Walk Participants and Walk Donors

$109M Raised by YOU since inception
The Lustgarten Foundation is grateful for our community’s dedication to transforming pancreatic cancer into a curable disease. Because of your generosity, Lustgarten-funded researchers are advancing research from the laboratory to the clinic and giving patients and their families renewed hope.

**FOUNDERS**
- Bill and Ellen Bell
- Cablevision Systems Corporation
- Mr. and Mrs. Frederick DeMatteis
- Mr. and Mrs. Charles F. Dolan
- Mr. and Mrs. James L. Dolan
- Mr. and Mrs. Amos B. Hostetter Jr.
- Mr. and Mrs. John T. Lockton III
- The Lustgarten Family
- McMullen Family Foundation
- Mr. and Mrs. F. F. Randolph Jr.
- Mr. and Mrs. Leonard Tow
- Charles B. Wang Foundation

**FY 2022**
This listing reflects gifts received from July 1, 2021–June 30, 2022. Donations of $1,000–$4,999 are listed on our website, Lustgarten.org.

**DIAMOND CIRCLE**
- $100,000+
- Glenn W. Bailey Foundation
- Adele S. Bennett Memorial Fund
- The Richard E Capri Foundation
- Creative Bath Products, Inc.
- FCSP Foundation
- Foundation For A Better World, Inc.
- The KDM Foundation
- The Marilyn Lichtman Foundation
- The McAdam Family Foundation
- Northwell Health Cancer Institute
- Pancreatic Cancer Center
- Kathryn Schulberg
- Adam Silver and Maggie Grise
- The Robert and Judith Sturgis Family Foundation
- Walsky Family Foundation

**SILVER CIRCLE**
- $25,000–$49,999
- The Elias, Genevieve and Georgianna Atoł Charitable Trust
- Baldor Specialty Foods Inc.
- The Robert J. Bauer Family Foundation
- Blavatnik Family Foundation
- Boston Scientific Corporation
- Charter Communications
- The DeMatteis Family Foundation
- Dime Community Bank
- Andree Wilderstein Dormeuil & Roger Dormeuil Foundation
- Rhonda Ellison
- Eugene and Sallyann Fama
- Robert Flicker
- Caren and Ross Frankel
- Ronald and Susan Frankel
- Mr. and Mrs. Kenneth Fuirst
- The Gay Libertarian Fund

**GOLD CIRCLE**
- $50,000–$99,999
- AMC Networks
- Apollo Global Management
- Leslie B. Barnett Foundation
- Stephen & Mary Birch Foundation
- Robert Black Charitable Foundation
- Mark Broxmeyer Memorial Fund

**BRONZE CIRCLE**
- $10,000–$24,999
- 7M Ranch Fund
- Abramson Family Foundation
- Louis and Anne Abrons Foundation, Inc.
- Howard Adler
- The Warren Alpert Foundation
- AmazonSmile Foundation
- AngioDynamics
- Rita A. Aranow Family Fund
- Yonat Assayag
- Bahnik Foundation, Inc.
- Andrea Balducci
- Bank of America
- Bank of Nova Scotia
- Baptist Health South Florida
- Judith and Peter Baum
- Marc Becker
- Caryn Seidman-Becker
- Linda Berger
- Berro Family Foundation, Inc.
- Bethpage Federal Credit Union
- BlackEdge Capital
- Richard and Sara Blomquist
- BNP Paribas USA
- Bonner Family Private Foundation, Inc.
- Peter BonTempo
- Debra Bottoms
- Boyle Family Foundation
- Bristol Myers Squibb Company
- The Robert and Marion Schamann Brozowski Foundation
- Mr. Salvatore M. Calli
- Thomas Caniano
- Carolann Catalogne
- Richard and Carol Chadakoff
- CIT Group Payment Services
- James Cotter
- Cravath, Swaine & Moore LLP
- J. Keith Davidson
- Melodee Davis
- Shelley and John Day
- Francesca DeLeo and Jeffrey Paraschak
- Mary Dix
- Dolan Family Fund at the Cleveland Foundation
- Dollar Bill Foundation
- Gloria Duffy
- Dr. Joan Egrie
<table>
<thead>
<tr>
<th>Benefactor</th>
<th>Amount</th>
</tr>
</thead>
</table>
Patricia Lehmann
Iris Lerner
Charles and Margaret Levin Family Foundation, Inc.
Jeffrey and Lauren Levin
Thalia and George Liberatos Foundation, Inc.
Paul and Suzanne Lipsky
Carol Ludwig
Charmaine Malachinski
Robert Manuso
John Marcato
Steve Martocci
Donna Mason
The Virginia Metzler Family Charitable Foundation
Diane Miller
John and Tenilee Moehling
The Moloney Family Foundation
Moskowitz Family Philanthropic Fund at Jewish National Fund
Mountain Ash Properties, LLC
Susan Neuberg
The Nielsen Company, Inc.
John O’Brien
Oresky & Associates, PLLC
Erika and Tom Padgett
Jacqueline Page
Dr. Felicia Pagliuca and Mr. Joe Pagliuca
Chris Parton
Leslie Patel
Perelson Weiner LLP Certified Public Accountants
Roslyn Persky
Robert Pittman
Jeffrey and Jodi Pliskin
John Powers
Jeanette Price
PricewaterhouseCoopers LLP
Joan Pullen
Raising Hope for Others
John Railson
Mrs. F. F. Randolph, Jr.
The Renard Family
Arthur Rettinger and Debra Schwartz
Ruth Ann Rhoads
Baker Rickailla
Dr. Alan E. Rosenau
Raymond Ross
Tammy Ross
Marc Rossi
Jayne Roth
James Rowley
Steven and Jacyn Rubin
Maurice and Lena Russo
Family Foundation
James Sarka
Ryan Scheinfeld
Kenneth Schneider
Anne Schnesel
Anthony Sciandra
Mario Sciandra
Second Evangelical Lutheran Church
Second Paramus Associates LLC
Gregg and Monique Selbert
The Seidenberg Family Foundation, Inc.
Kenneth and Nikki Seiff
Michael and Carol Sesnowitz
Thomas Shapiro
Annie Shon-Ng
William and Sylvia Silberstein Foundation, Inc.
Jason Singer
Dianne and Michael Sirek
Charles W. Slack Communications
Marvin and Carol Soroos
Laurence and Anne Sperry
The Spionkop Charitable Trust
Clare Stadtmayer Memorial Fund
Margot and Howard Steinberg Charitable Foundation
Mrs. Pamela June Steinberg
The Dr. Travis Stork Fund
Strategic Wealth Planning, Inc.
Dr. and Mrs. Mark R. Sultan
Leah Teeter
Darshan Timbadia
Jonathan Tisch
Dave Trampel
Tri-Star Construction
Ms. Clare M. Tussel and Family
Two Trees Management Company
Carolyn Usher-Torres
Rosalie Van Dam
Christine Viola-Weiss
Dr. and Mrs. Robert F. Vizza
William W. Wayco Memorial Fund
Kenneth and Joanne Weinman
Weinshel Goldfarb Foundation, Inc.
Pepi Weiss
Larry and Carol Weissenberg
West Haven, CT Elks Lodge #1537
Gabriel Winin
Wrobel Family Foundation
Brian Younghans

ESTATES
$100,000–$999,999
Estate of Helene Fortunoff
Estate of Robert B. Francoeur
Estate of Jeanette M. Kordiak
Estate of Stefan Pischinger
Estate of Betty Ann Utterback
$50,000–$99,999
Estate of Charlene Cosman
Estate of Kathryn D. Wriston*
$25,000–$49,999
William T. Barkley and Aileen C. Johnson Family Trust
Estate of Mary Brenneisen**
Estate of Frances Fried
$10,000–$24,999
Estate of Christina L. Cruikshank
Estate of Elinor Ann Hamm
Estate of Michael Inden
$5,000–$9,999
Estate of Faye A. Rozovsky
Estate of Joel H. Sachs

IN-KIND DONORS
The Lustgarten Foundation is grateful for the organizations that have generously donated their products and services to help accelerate progress in pancreatic cancer research.

1010 WINS
CBS2 New York
KPMG LLP
Newsday
Paul Hastings, LLC

MATCHING GIFTS
The Lustgarten Foundation thanks the hundreds of corporate employees across the country who have donated and the employers who have generously matched these donations.

AbbVie Matching Gifts
Apollo Global Management
Matching Gifts
Apple, Inc. Matching Gifts
Bank of America Foundation Matching Gifts
BMO Financial Group Matching Gifts
Bristol Myers Squibb Foundation
Matching Gifts Program
Cisco Systems Foundation
Matching Gifts Program
Colgate-Palmolive Matching Gifts
DocuSign Matching Gifts
Google Matching Gifts
The William & Flora Hewlett Foundation Matching Gifts Program
Intel Matching Gifts
Johnson & Johnson Matching Gifts
JP Morgan Chase Matching Gifts
Liberty Mutual Matching Gifts
Microsoft Matching Gifts
Morgan Stanley Matching Gifts
New York Life–YourCause Employee Giving
Nvidia Matching Gifts
UnitedHealth Group Matching Gifts
Verizon Matching Gifts

LEGACY OF HOPE SOCIETY
Legacy of Hope donors are making a lasting impact on the lives of future pancreatic cancer patients by including the Foundation in their wills. These gifts ensure the work of the Foundation will endure until a cure for pancreatic cancer can be discovered.

Joseph Arena and Thomas D’Eletto, MD
Maxine Bentolla
Gail V. Coleman
Karen S. Hogg
Susan Martinson
William O’Connell
Steven Oppen
Sally and John Schlachtenhaufen
Lucy Shostak
Petr Silverman
Patrick J. and Diana L. Swanick
Joanne and Kenneth Weinman
Hope and Gavin Wolfe

*final distribution of $45,979,956 gift
**final distribution of $16,676,191 gift

Monthly Donors Fuel Progress!

Monthly donors provide the reliable flow of ongoing contributions that drive new breakthroughs in early detection, drug development, and personalized medicine, giving patients the best chance for survival and quality of life. When you donate, please consider becoming a monthly donor!
leadership.

Board of Directors

Andrew Lustgarten
Chairman, Lustgarten Foundation; Director, MSG Sports Corp.

James L. Dolan
Vice Chairman, Lustgarten Foundation; Executive Chairman and Chief Executive Officer, MSG Entertainment; Executive Chairman, MSG Sports Corp.; Interim Executive Chairman, AMC Networks Inc.

Adam Silver
Vice Chairman, Lustgarten Foundation; Commissioner, National Basketball Association

Charles F. Dolan
Chairman Emeritus, Lustgarten Foundation; Chairman Emeritus, AMC Networks; Former Chairman, Cablevision Systems Corporation

Robert F. Vizza, PhD
Chairman Emeritus, Lustgarten Foundation

William Bell
Treasurer, Lustgarten Foundation (term ended 6/30/22); Former Vice Chairman, Cablevision Systems Corporation

Philip D'Ambrosio
Treasurer, Lustgarten Foundation (effective 7/1/22); Former Vice President and Treasurer, MSG Entertainment Corp.

Jennie Fortunoff
Secretary, Lustgarten Foundation; Principal, Esterow Events & Consulting, Inc.

Sommer Bazuro, PhD
Chief Medical Officer, IPG Health

John Cobb
Partner, Paul Hastings

Jessica Lustgarten Courtemanche
Vice President/Director, Data and Analysis, DigitasLBi North America

Quentin Dolan
Investment Director, MSG Sports Corp.; Director, MSG Sports Corp.

Kenneth Goodman, MD, FACC
Former Director, Department of Radiology and Attending Physician, St. Francis Hospital

Marcia Lustgarten
Former Director, Optimum Community, Cablevision Systems Corporation

Sheila Mahony
Former Executive Vice President, Communication, Government and Public Affairs, Cablevision Systems Corporation

Charles R. Schueler
Former Executive Vice President, Media, and Community Relations, Cablevision Systems Corporation

Willa Shalit
Co-Founder and Principal, RTM Limited; Co-Founder, Let’s Win! Pancreatic Cancer Foundation

Linda Tantawi
CEO, Lustgarten Foundation

Scientific Advisory Board

David Tuveson, MD, PhD
Chief Scientist, Lustgarten Foundation; Cold Spring Harbor Laboratory Cancer Center

Elizabeth M. Jaffee, MD
Chief Medical Advisor, Lustgarten Foundation; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Peter Allen, MD
Duke University

Dafna Bar-Sagi, PhD
NYU Langone

Luis Diaz, MD
Memorial Sloan Kettering Cancer Center

Ted Hong, MD
Massachusetts General Hospital

Tyler Jacks, PhD
Koch Institute, MIT

Reuben Shaw, PhD
Salk Institute

Selwyn Vickers, MD
Memorial Sloan Kettering Cancer Center

Bert Vogelstein, MD
The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Jen Jen Yeh, MD
UNC School of Medicine

Corporate Advisory Board, Emeritus

The Honorable Jimmy Carter
39th U.S. President, Honorary Chairman

Frank A. Bennack, Jr.
Executive Vice Chairman and Former Chief Executive Officer, Hearst Corporation

Barry Diller
Chairman & Senior Executive, IAC/InterActiveCorp and Expedia, Inc.

John S. Hendricks
Founder & Former Chairman, Discovery Communications

Mel Karmazin
Former Chief Executive Officer, Sirius XM Radio, Inc.; Co-Founder, Infinity Broadcasting

Gerald M. Levin
Former Chairman and Chief Executive Officer, Time Warner, Inc.

John C. Malone
Former President and Chief Executive Officer, Tele-Communications Inc.; Chairman, Liberty Media Corporation

Rupert Murdoch
Executive Chairman, News Corp; Chairman, Fox Corporation

Tom Rogers
Executive Chairman, WinView; Founder, CNBC and MSNBC

Sir Howard Stringer
Non-Executive Director, British Broadcasting Corporation; Former Chairman and CEO, Sony Corporation

Wynal Design, Inc.
The Lustgarten Foundation is the largest private funder of pancreatic cancer research in the world, funding preeminent pancreatic cancer researchers, driving the pursuit of bold and innovative science toward earlier detection and better treatments, transforming pancreatic cancer into a curable disease. The Foundation funds research where creative risks yield high rewards to accelerate and expand life-saving treatment options. We believe time is everything to patients and their families, and that community is power. Lustgarten programs and events provide people affected by pancreatic cancer a voice and a place to create hope, together.

100% of all donations fuel the research to advance understanding of this complex, devastating and historically underfunded cancer.